Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) by Seini Moimoi | Feb 2, 2022 | Portfolio News
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib by Seini Moimoi | Jan 25, 2022 | Portfolio News
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis by Seini Moimoi | Jan 25, 2022 | Portfolio News
Murj Releases Next Generation Advisory Management for Implantable Cardiac Devices by Seini Moimoi | Jan 25, 2022 | Portfolio News
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence by Seini Moimoi | Jan 25, 2022 | Portfolio News
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH by Seini Moimoi | Jan 24, 2022 | Portfolio News
Eargo Applauds Proposed Rule for OTC Hearing Aids and Submits Public Comments to FDA by Seini Moimoi | Jan 20, 2022 | Portfolio News
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients by Seini Moimoi | Jan 19, 2022 | Portfolio News
Orbus Therapeutic’s Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment by Seini Moimoi | Jan 19, 2022 | Portfolio News
Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment by Seini Moimoi | Jan 19, 2022 | Portfolio News
